Caris Life Sciences

Caris MPI, Inc. is a US-based company focused on innovative molecular profiling solutions for cancer treatment, utilizing advanced technologies to support personalized medicine and enhance patient care. Founded in 1996 and headquartered in Irving, US, Caris MPI, Inc. specializes in molecular profiling for oncology.

The founders, including Charles Modlin and David Halbert, have a history of involvement in the healthcare sector. The company has engaged in six investment deals and recently received USD 168. 00 mn in a GROWTH funding round led by Braidwell Lp, reflecting confidence in its strategic direction. Caris Life Sciences specializes in advanced molecular profiling solutions aimed at revolutionizing cancer care through personalized medicine.

Their core product offerings include Caris Assure®, which utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach for whole exome and transcriptome sequencing from blood samples, and MI Profile®, which provides comprehensive testing for over 23,000 genes alongside protein analysis. These products deliver high-quality molecular information to oncologists and patients, facilitating informed treatment decisions based on individual molecular characteristics. Caris caters to a diverse clientele that includes oncologists, biopharmaceutical companies, and research institutions across various global markets, including North America, Europe, and parts of Asia, addressing key challenges in cancer treatment. Caris Life Sciences generates revenue through a structured business model centered around its molecular profiling products and services.

Transactions typically occur on a B2B basis, where healthcare providers and pharmaceutical companies order Caris's diagnostic tests to inform treatment plans for cancer patients. The pricing structure reflects the complexity and comprehensiveness of the services offered, with prominent products like Caris Assure® and MI Profile® forming the backbone of their revenue streams. The company engages in partnerships with healthcare facilities and biopharma companies to enhance its service offerings, ensuring that clients receive tailored support throughout the treatment continuum. Caris MPI, Inc.

plans to leverage recent funding from its GROWTH round to advance new product development and market expansion. The company aims to introduce enhanced molecular profiling products in 2024, targeting new markets in Europe and Asia to diversify its reach. Additionally, Caris MPI, Inc. is expected to utilize its growth capital to solidify partnerships and enhance service delivery, focusing on comprehensive cancer care solutions.